Receiving interferon-free regimens led to patient-reported outcome (PRO) improvement during treatment for hepatitis C virus (HCV) and after SVR regardless of opioid substitution therapy (OST) status, a recent study found. Patients were enrolled in phase 3 clinical trials of sofosbuvir and completed 4 PRO instruments: SF-36V2, FACIT-F, CLDQ-HCV, and WPAI-HCV before, during, and post-treatment. 8,450 HCV individuals were included; 407 (4.8%) were on OST. Researchers found:
- At baseline, OST participants had significantly lower PRO scores.
- By treatment completion, those receiving IFN+RBV+SOF experienced significant decreases in PROs regardless of OST use.
- Those receiving IFN-free RBV+ regimens had significant but smaller PRO decreases; similar in OST and non-OST.
- Those treated with IFN/RBV-free regimens showed improvement in nearly all PROs during treatment which was more pronounced in OST individuals.
Stepanova M, Thompson A, Doyle J, Younossi I, de Avila L, Younossi ZM. Hepatitis C patients receiving opioid substitution therapy experience improvement in patient-reported outcomes following treatment with interferon-free regimens. [Published online ahead of print December 26, 2017]. J Infect Dis. doi:10.1093/infdis/jix681.
This Week's Must Reads
New IDSA Guideline for Management of OPAT, Clin Infect Dis; ePub 2018 Nov 13; Norris, et al
Immunocompromised Children with Influenza, J Pediatric Infect Dis Soc; ePub 2018 Oct 25; Collins, et al
OPAT Outcomes in SNFs vs HHCs, Open Forum Infect Dis; ePub 2018 Oct 24; Townsend, et al
HIV-associated Cryptococcal Meningitis at Higher CD4 Counts, J Infect Dis; ePub 2018 Oct 16; Tugume, et al
Mycoplasma Genitalium Infections & STIs, Clin Infect Dis; ePub 2018 Oct 23; Lillis, et al
Must Reads in Hepatitis
Mortality in US Patients with Chronic HBV, Clin Infect Dis; ePub 2018 Jul 28; Bixler, et al
Pregnancy Outcomes in Women with HBV , Open Forum Infect Dis; ePub 2018 Jun 9; Bajema, et al
HBV Prevention in Foreign-Born Women, Clin Infect Dis; ePub 2018 Jun 1; Kilmer, et al
ACIP Recommends Hepatitis B Vaccine for Adults, MMWR; 2018 Apr 20; Schillie, Harris, et al
HCV Treatment as Prevention in PWIDs, Lancet; 2018 Feb; Zelenev, Li, et al